Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03013491
Title A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors CytomX Therapeutics
Indications

Advanced Solid Tumor

lymphoma

Therapies

CX-072 + Ipilimumab

CX-072 + Vemurafenib

CX-072

Age Groups: adult | senior
Covered Countries USA | ESP


No variant requirements are available.